ABSTRACT
Unintended treatment interruptions during a course of radiotherapy can lead to extended overall treatment times which allow increased tumour cell repopulation to occur. Extra dose may therefore be required to offset any loss of tumour control. However, the manner in which the extra dose is delivered requires careful consideration in order to avoid the risk of increased normal tissue toxicity. Radiobiological modelling techniques can allow quantitative examination of such problems and may be used to derive revised pattens of radiation delivery which can help restore a degree of tumour control whilst limiting the likelihood of excess normal tissue morbidity. Unintended treatment interruptions can occur in any radiotherapy department but the rapid spread of the Covid-19 pandemic caused a major increase in the frequency of such interruptions due to staff and patient illness and the consequent self-isolation requirements. This article summarises the radiobiological considerations and caveats involved in assessing treatment interruptions and outlines the UK experience of dealing with the new challenges posed by Covid-19. The world-wide need for more education programmes in cancer radiobiology is highlighted.
ABSTRACT
Compensatory dose calculations to mitigate the deleterious effect of unscheduled treatment interruptions remain important. They may be increasingly required during and after epidemics, as with the present Covid-19 virus. The information presented to those involved in the actual dose estimations is often limited, thereby increasing the likelihood of confusion, further time delays and possibly incorrect decisions. This article sets out what aspects need to be considered by the Clinical Oncologist (or Radiation Oncologist), and the reasons why, in order to provide greater clarity. The key issues are: (a) the biological nature of the tumour (and hence its repopulation potential), (b) patient age and pre-existing medical risk factors that influence radiation tolerance, the use of chemotherapy, surgery etc, (c) the acceptable dose limits of the relevant normal tissues at risk and (d) consideration of the possibility of further field size adjustments, a change in treatment plan or acceptance of a greater role for alternative forms of radiation treatment (e.g. brachytherapy, electron boosts, etc.) or reliance on radical surgery. Only then can a compensatory schedule be more safely estimated.